Search

Your search keyword '"immunopharmacology"' showing total 34 results
Start Over Descriptor "immunopharmacology" Database Gale General OneFile
34 results on '"immunopharmacology"'

1. New Study Findings from National Institutes for Food and Drug Control Illuminate Research in Immunotherapy (Changes of Physicochemical Properties and Immunomodulatory Activity of Polysaccharides During Processing of Polygonum multiflorum Thunb)

Subjects
Polysaccharides -- Chemical properties -- Health aspects, Polygonum -- Chemical properties -- Health aspects, Immunopharmacology, Health
Abstract

2022 JUL 9 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on immunotherapy are discussed in a new report. According to [...]

Published
2022

2. TAP-1 technology corroborated in models of skin cancer

Subjects
GeneMax Corp, Immunopharmacology, Health, Obesity, Immunology, Dermatology
Abstract

2004 JUN 12 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX) announced its patented TAP-1 (transporters associated with antigen processing) anticancer technology is effective in generating immune responses against melanoma [...]

Published
2004

3. Technical Alert: GMXX, MAMA, MGM, MMM, JILL

Subjects
GeneMax Corp, Immunopharmacology, Business, Business, international
Abstract

M2 PRESSWIRE-16 March 2004-InvestSource Inc.: Technical Alert: GMXX, MAMA, MGM, MMM, JILL(C)1994-2004 M2 COMMUNICATIONS LTD RDATE:03162004 GeneMax Corporation (OTCBB: GMXX), Mamma.com Incorporated (NYSE: MAMA), Metro-Goldwyn-Mayer Incorporated (NYSE: MGM) 3M Company [...]

Published
2004

4. InvestSource Coverage Alerts: GMXX, MSO, SBL, PFE, JNJ

Subjects
Symbol Technologies Inc., GeneMax Corp, Laser industry, Immunopharmacology, Business, Business, international
Abstract

M2 PRESSWIRE-8 March 2004-InvestSource Inc.: InvestSource Coverage Alerts: GMXX, MSO, SBL, PFE, JNJ(C)1994-2004 M2 COMMUNICATIONS LTD RDATE:03082004 GeneMax Corporation (OTCBB: GMXX), Martha Stewart Living Omnimedia Incorporated (NYSE: MSO), Symbol Technologies, [...]

Published
2004

5. InvestSource Coverage Alerts: GMXX, CEGE, BSX, VTIV, BIIB, JNJ

Subjects
GeneMax Corp, Immunopharmacology, Business, Business, international
Abstract

M2 PRESSWIRE-5 March 2004-InvestSource Inc.: InvestSource Coverage Alerts: GMXX, CEGE, BSX, VTIV, BIIB, JNJ(C)1994-2004 M2 COMMUNICATIONS LTD RDATE:03052004 GeneMax Corporation (OTCBB: GMXX), Cell Genesys Incorporated (Nasdaq: CEGE), Boston Scientific Corporation [...]

Published
2004

7. GeneMax Corp. announces agreement with Molecular Medicine BioServices, Inc. for the production of TAP Cancer Vaccine

Subjects
GeneMax Corp, Molecular Medicine BioServices Inc., Immunopharmacology, Pharmaceutical industry, Business, News, opinion and commentary
Abstract

Blaine, Washington, September 9 /PRNewswire/ -- GeneMax Corp. (OTC Bulletin Board: GMXX; Frankfurt and Berlin: GX1) today announced an amended contractual agreement with Molecular Medicine BioServices, Inc. of San Diego, [...]

Published
2003

11. TAP-1 technology corroborated in models of skin cancer

Subjects
GeneMax Corp, Immunopharmacology, Immunology, Dermatology, Pharmaceuticals and cosmetics industries
Abstract

2004 JUN 11 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX) announced its patented TAP-1 (transporters associated with antigen processing) anticancer technology is effective in generating immune responses against melanoma [...]

Published
2004

12. TAP-1 technology corroborated in models of skin cancer

Subjects
GeneMax Corp, Immunopharmacology, Dermatology, Immunology, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2004 JUN 9 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX) announced its patented TAP-1 (transporters associated with antigen processing) anticancer technology is effective in generating immune responses against melanoma [...]

Published
2004

13. TAP-1 technology corroborated in models of skin cancer

Subjects
GeneMax Corp, Immunopharmacology, Oncology, Dermatology, Immunology
Abstract

2004 JUN 8 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX) announced its patented TAP-1 (transporters associated with antigen processing) anticancer technology is effective in generating immune responses against melanoma [...]

Published
2004

14. TAP-1 technology corroborated in models of skin cancer

Subjects
GeneMax Corp, Dermatology, Immunology, Immunopharmacology
Abstract

2004 JUN 7 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX) announced its patented TAP-1 (transporters associated with antigen processing) anticancer technology is effective in generating immune responses against melanoma [...]

Published
2004

15. TAP-1 technology corroborated in models of skin cancer

Subjects
GeneMax Corp, Immunopharmacology, Dermatology, Immunology
Abstract

2004 JUN 7 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX) announced its patented TAP-1 (transporters associated with antigen processing) anticancer technology is effective in generating immune responses against melanoma [...]

Published
2004

16. Company moves towards clinical trials with TAP cancer vaccine

Subjects
GeneMax Corp, Biological products -- Health aspects, Cancer, Clinical trials, Cancer vaccines, Immunotherapy, Immunopharmacology, Oncology, Immunology
Abstract

2003 NOV 25 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX) announced that its contract manufacturer has begun construction of the GeneMax gene vector, containing TAP (transporters associated with antigen [...]

Published
2003

17. Company moves towards clinical trials with TAP cancer vaccine

Subjects
GeneMax Corp, Biological products -- Health aspects, Cancer, Cancer vaccines, Clinical trials, Immunotherapy, Immunopharmacology, Immunology
Abstract

2003 NOV 24 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX) announced that its contract manufacturer has begun construction of the GeneMax gene vector, containing TAP (transporters associated with antigen [...]

Published
2003

18. GeneMax Corp. announces agreement for the production of TAP cancer vaccine

Subjects
GeneMax Corp, Immunotherapy, Cancer -- Care and treatment, Cancer vaccines, Biological products -- Health aspects, Immunopharmacology, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2003 OCT 8 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX) announced an amended contractual agreement with Molecular Medicine BioServices, Inc., of San Diego, California, for the production of its [...]

Published
2003

19. GeneMax Corp. announces agreement for the production of TAP cancer vaccine

Subjects
GeneMax Corp, Biological products -- Health aspects, Oncology, Immunopharmacology, Immunology
Abstract

2003 OCT 7 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX) announced an amended contractual agreement with Molecular Medicine BioServices, Inc., of San Diego, California, for the production of its [...]

Published
2003

20. GeneMax Corp. announces agreement for the production of TAP cancer vaccine

Subjects
GeneMax Corp, Biological products -- Health aspects, Cancer, Cancer vaccines, Immunopharmacology, Immunotherapy, Immunology
Abstract

2003 OCT 6 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX) announced an amended contractual agreement with Molecular Medicine BioServices, Inc., of San Diego, California, for the production of its [...]

Published
2003

21. GeneMax Corp. announces agreement for the production of TAP cancer vaccine

Subjects
GeneMax Corp, Biological products -- Health aspects, Immunopharmacology, Immunology
Abstract

2003 OCT 6 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX) announced an amended contractual agreement with Molecular Medicine BioServices, Inc., of San Diego, California, for the production of its [...]

Published
2003

22. GeneMax Corp. announces agreement for the production of TAP cancer vaccine

Subjects
GeneMax Corp, Biological products -- Health aspects, Cancer, Cancer vaccines, Immunotherapy, Immunopharmacology, Immunology
Abstract

2003 OCT 6 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX) announced an amended contractual agreement with Molecular Medicine BioServices, Inc., of San Diego, California, for the production of its [...]

Published
2003

23. GeneMax enters PER.C6 license agreement with Dutch biotech company

Subjects
Crucell N.V., GeneMax Corp, Cytology, Biotechnology, Gene therapy, Specialty chemicals, Immunopharmacology, Pharmaceuticals and cosmetics industries
Abstract

2003 SEP 12 - (NewsRx.com & NewsRx.net) -- Dutch biotechnology company Crucell, N.V., (CRXL) and U.S.-based GeneMax Corp. (GMXX) announced that they have entered a license agreement for Crucell's PER.C6 [...]

Published
2003

24. GeneMax enters PER.C6 license agreement with Dutch biotech company

Subjects
Crucell N.V., GeneMax Corp, Cytology, Biotechnology, Specialty chemicals, Immunopharmacology, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2003 SEP 10 - (NewsRx.com & NewsRx.net) -- Dutch biotechnology company Crucell, N.V., (CRXL) and U.S.-based GeneMax Corp. (GMXX) announced that they have entered a license agreement for Crucell's PER.C6 [...]

Published
2003

25. GeneMax enters PER.C6 license agreement with Dutch biotech company

Subjects
Crucell N.V., GeneMax Corp, Cytology, Biotechnology, Gene therapy, Specialty chemicals, Immunopharmacology, Biotechnology industry, Biological sciences, Business
Abstract

2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Dutch biotechnology company Crucell, N.V., (CRXL) and U.S.-based GeneMax Corp. (GMXX) announced that they have entered a license agreement for Crucell's PER.C6 [...]

Published
2003

26. GeneMax enters PER.C6 license agreement with Dutch biotech company

Subjects
Crucell N.V., GeneMax Corp, Immunopharmacology, Gene therapy, Biotechnology, Cytology
Abstract

2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Dutch biotechnology company Crucell, N.V., (CRXL) and U.S.-based GeneMax Corp. (GMXX) announced that they have entered a license agreement for Crucell's PER.C6 [...]

Published
2003

27. GeneMax enters PER.C6 license agreement with Dutch biotech company

Subjects
Crucell N.V., GeneMax Corp, Immunopharmacology, Gene therapy, Biotechnology, Cytology
Abstract

2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Dutch biotechnology company Crucell, N.V., (CRXL) and U.S.-based GeneMax Corp. (GMXX) announced that they have entered a license agreement for Crucell's PER.C6 [...]

Published
2003

28. GeneMax enters PER.C6 license agreement with Dutch biotech company

Subjects
Crucell N.V., GeneMax Corp, Immunopharmacology, Gene therapy, Biotechnology, Cytology
Abstract

2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Dutch biotechnology company Crucell, N.V., (CRXL) and U.S.-based GeneMax Corp. (GMXX) announced that they have entered a license agreement for Crucell's PER.C6 [...]

Published
2003

29. Agreement reached for the production of cancer vaccine

Subjects
GeneMax Corp, Molecular Medicine BioServices Inc., Immunopharmacology, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2003 APR 16 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX; GX1) announced a contractual agreement with Molecular Medicine BioServices, Inc., of San Diego, California, for the production of its [...]

Published
2003

30. Agreement reached for the production of cancer vaccine

Subjects
GeneMax Corp, Molecular Medicine BioServices Inc., Immunopharmacology
Abstract

2003 APR 14 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX; GX1) announced a contractual agreement with Molecular Medicine BioServices, Inc., of San Diego, California, for the production of its [...]

Published
2003

31. Agreement reached for the production of cancer vaccine

Subjects
GeneMax Corp, Molecular Medicine BioServices Inc., Immunopharmacology
Abstract

2003 APR 14 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX; GX1) announced a contractual agreement with Molecular Medicine BioServices, Inc., of San Diego, California, for the production of its [...]

Published
2003

32. Method for identifying new tumor antigens developed

Subjects
GeneMax Corp, Immunopharmacology, Health, Pharmaceuticals and cosmetics industries
Abstract

2003 APR 4 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX; GX1) announced that it has added to its technology portfolio by expanding the license with the University of British [...]

Published
2003

33. Method for identifying new tumor antigens developed

Subjects
GeneMax Corp, Immunopharmacology, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2003 APR 2 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX; GX1) announced that it has added to its technology portfolio by expanding the license with the University of British [...]

Published
2003

34. Ribi ImmunoChem Research: helping the body fight cancer

Author

Lewis, Ricki

Subjects
Ribi ImmunoChem Research Inc. -- Management, Biotechnology industry -- Management, Cancer -- Drug therapy, Immunopharmacology, Business, Computers and office automation industries, High technology industry
Published
1987

Catalog

Books, media, physical & digital resources
See catalog results